6 Realities of Genomic Research
By Dan Koboldt,
Mass Genomics
| 06. 19. 2015
Untitled Document
The rise of next-generation sequencing has worked wonders for the field of genetics and genomics. It’s also generated a considerable amount of hype about the power of genome sequencing, particularly the possibility of individualized medicine based on genetic information. The rapid advances in technology — most recently, the Illumina X Ten system — have made heretofore impossible large-scale whole-genome sequencing studies feasible. I’ve already written about some of the possible applications of inexpensive genome sequencing.
I’m as excited about this as anyone (with the possible exception of Illumina). Even so, we should keep in mind that not everything is unicorns and rainbows when it comes to genomic research. Here are some observations I’ve made about sequencing-empowered genomic research over the past few years.
1. There is never enough power
“Power” is a term that’s being discussed more and more as we plan large-scale sequencing studies of common disease. In essence, it answers the question, “What fraction of the associated variants can we detect with this study design, given the number of samples, inheritance pattern, penetrance, etc.?” Several years ago, when...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
